Keyword Analysis & Research: morphosys news
Keyword Research: People who searched morphosys news also searched
Search Results related to morphosys news on Search Engine
-
MorphoSys Enters into Business Combination Agreement to be …
https://www.morphosys.com/en/news/morphosys-enters-business-combination-agreement-be-acquired-novartis-eu-27-billion-equity
PLANEGG/MUNICH, Germany – February 5, 2024 – MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced the company entered into a Business Combination Agreement with Novartis data42 AG and Novartis AG (hereinafter collectively referred to as “Novartis”) based on Novartis’ intention to submit a voluntary public takeover offer for all ...
DA: 36 PA: 27 MOZ Rank: 6
-
All News | Morphosys de
https://www.morphosys.com/en/news/all
MorphoSys Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 Financial Guidance and Reduces Financial Liability. PDF. 30.01.2024. adhoc.
DA: 29 PA: 22 MOZ Rank: 82
-
MorphoSys’ Phase 3 Study of Pelabresib in Myelofibrosis …
https://www.morphosys.com/en/news/morphosys-phase-3-study-pelabresib-myelofibrosis-demonstrates-statistically-significant
Nov 20, 2023 · Media Release. Planegg/Munich, Germany, November 20, 2023. MorphoSys’ Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction. MANIFEST-2 met primary endpoint, nearly doubling SVR35 response rate (66% versus 35%)
DA: 54 PA: 76 MOZ Rank: 78
-
MorphoSys’ Phase 3 Study of Pelabresib in Myelofibrosis …
https://finance.yahoo.com/news/morphosys-phase-3-study-pelabresib-213000171.html
Nov 20, 2023 · PLANEGG/MUNICH, Germany, November 20, 2023 -- ( BUSINESS WIRE )--MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced strong topline results from the Phase 3 MANIFEST-2 study investigating...
DA: 80 PA: 68 MOZ Rank: 36
-
Novartis to Buy MorphoSys for $2.9 Billion; Deal Seen Closing in 1H
https://www.wsj.com/tech/biotech/novartis-to-buy-morphosys-for-2-9-billion-deal-seen-closing-in-1h-625e6b48
Feb 5, 2024 · Novartis to Buy MorphoSys for $2.9 Billion; Deal Seen Closing in 1H - WSJ. Market Data Home. Companies. U.S. Stocks. Currencies Market Data. Mutual Funds & ETFs. Gerard Baker. Sadanand Dhume....
DA: 41 PA: 90 MOZ Rank: 49
-
MorphoSys Receives U.S. Antitrust Approval For Acquisition By …
https://markets.businessinsider.com/news/stocks/morphosys-receives-u-s-antitrust-approval-for-acquisition-by-novartis-1033187212
RTTNews. Mar. 22, 2024, 02:56 AM. (RTTNews) - MorphoSys AG (MOR) announced the receipt of U.S. antitrust clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 in connection with ...
DA: 50 PA: 50 MOZ Rank: 30
-
MorphoSys AG Reports Fourth Quarter and Full Year 2023 …
https://finance.yahoo.com/news/morphosys-ag-reports-fourth-quarter-200200996.html
Mar 13, 2024 · PLANEGG/MUNICH, Germany, March 13, 2024--MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the fourth quarter and the full year 2023.
DA: 83 PA: 91 MOZ Rank: 21
-
MorphoSys’ Pelabresib Improves All Four Hallmarks of …
https://finance.yahoo.com/news/morphosys-pelabresib-improves-four-hallmarks-003100419.html
Dec 11, 2023 · PLANEGG/MUNICH, Germany, December 11, 2023 -- ( BUSINESS WIRE )--MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced comprehensive results from the Phase 3 MANIFEST-2 study investigating...
DA: 87 PA: 91 MOZ Rank: 23
-
Exclusive-Novartis in the lead to acquire cancer drug developer
https://news.yahoo.com/exclusive-novartis-lead-acquire-cancer-152919282.html
Feb 5, 2024 · Recommended Stories. (Reuters) -Drug maker Novartis AG is in advanced talks to acquire MorphoSys AG, a developer of cancer treatments that has a market value of 1.6 billion euros ($1.7 billion),...
DA: 64 PA: 29 MOZ Rank: 1
-
Novartis to acquire cancer-focused MorphoSys for $2.9 billion
https://www.reuters.com/markets/deals/novartis-acquires-cancer-drug-developer-morphosys-29-bln-2024-02-05/
Feb 6 (Reuters) - Drugmaker Novartis AG (NOVN.S) said it will acquire MorphoSys AG (MORG.DE), a developer of cancer treatments, for 2.7 billion euros ($2.9 billion), adding a promising rare...
DA: 24 PA: 93 MOZ Rank: 95